This inventor holds 1 USPTO granted patent. Top assignee: Eli Lilly and Company. Active years: 1994.
Company Filing History:
Years Active: 1994
Title: Amy E Hamilton: Innovator in Recombinant DNA Technology
Introduction
Amy E Hamilton is a prominent inventor based in Indianapolis, IN (US). She has made significant contributions to the field of biotechnology, particularly in the development of recombinant DNA compounds. Her work has implications for the diagnosis and treatment of various adenocarcinomas.
Latest Patents
Amy holds a patent for "Vectors and DNAs for expression of a human adenocarcinoma antigen." This invention comprises novel recombinant DNA compounds that encode a 40,000 dalton adenocarcinoma antigen recognized by monoclonal antibody KS 1/4. The eukaryotic and prokaryotic expression vectors constructed from this invention drive the expression of KSA when transformed into an appropriate host cell. The recombinant-produced KSA is useful for diagnosing, prognosing, and treating disease states, including adenocarcinomas of the lung, prostate, breast, ovary, and colon/rectum.
Career Highlights
Amy is currently employed at Eli Lilly and Company, where she continues to advance her research in biotechnology. Her innovative work has positioned her as a key figure in the development of therapeutic solutions for cancer treatment.
Collaborations
Amy has collaborated with notable colleagues, including Thomas F Bumol and Robert Alan Gadski. These partnerships have further enhanced her research and contributions to the field.
Conclusion
Amy E Hamilton is a trailblazer in recombinant DNA technology, with a focus on cancer research. Her patent and work at Eli Lilly and Company exemplify her commitment to advancing medical science and improving patient outcomes.